HER2 in Colorectal Cancer: The Long and Winding Road From Negative Predictive Factor to Positive Actionable Target
The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.
Abstract
Human epidermal growth factor receptor 2 ( HER2) is a well-known oncogenic driver in different tumors and an approved therapeutic target in breast and gastroesophageal cancer. In metastatic colorectal cancer, only 3% to 5% of patients present with HER2 alterations: somatic mutations and amplifications. HER2 was first assessed as a biomarker of resistance to anti- EGFR therapy; however, in more recent years, its role as a potential actionable target has emerged. In this article, we discuss the predictive and prognostic value of HER2 in metastatic colorectal cancer, its emerging role as an actionable therapeutic target, and its possible future developments.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Additionally, HER2 is commonly amplified or overexpressed in 7% to 47.4% of CRC patients, activating downstream signaling in a similar manner [81–83].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [83]
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
ERBB receptors and cancer: the complexity of targeted inhibitors
Hynes, N. E., & Lane, H. A. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1609 · Cited by 3,313
Grothey, A., Cutsem, E. V., Sobrero, A., Siena, S., Falcone, A., Ychou, M., Humblet, Y., Bouché, O., Mineur, L., Barone, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61900-x · Cited by 2,895
Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
Mayer, R. J., Van Cutsem, E., Falcone, A., Yoshino, T., Garcia-Carbonero, R., Mizunuma, N., Yamazaki, K., Shimada, Y., Tabernero, J., Komatsu, Y., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414325 · Cited by 1,431
Moasser, M. M. (2007) · Oncogene · doi:10.1038/sj.onc.1210477 · Cited by 1,219
HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target
Gravalos, C., & Jimeno, A. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn169 · Cited by 1,184
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer
Cortés, J., Kim, S.-B., Chung, W.-P., Im, S.-A., Park, Y. H., Hegg, R., Kim, M. H., Tseng, L.-M., Petry, V., Chung, C.-F., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2115022 · Cited by 1,175
Sartore-Bianchi, A., Trusolino, L., Martino, C., Bencardino, K., Lonardi, S., Bergamo, F., Zagonel, V., Leone, F., Depetris, I., Martinelli, E., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00150-9 · Cited by 1,016
Self-citationBertotti, A., Migliardi, G., Galimi, F., Sassi, F., Torti, D., Isella, C., Corà, D., Di Nicolantonio, F., Buscarino, M., Petti, C., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0109 · Cited by 939
Fukuoka, S., Hara, H., Takahashi, N., Kojima, T., Kawazoe, A., Asayama, M., Yoshii, T., Kotani, D., Tamura, H., Mikamoto, Y., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03296 · Cited by 890
Gusterson, B. A., Gelber, R. D., Goldhirsch, A., Price, K. N., Säve-Söderborgh, J., Anbazhagan, R., Styles, J., Rudenstam, C. M., Golouh, R., & Reed, R. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.7.1049 · Cited by 838
Arnold, D., Lueza, B., Douillard, J.-Y., Peeters, M., Lenz, H.-J., Venook, A., Heinemann, V., Van Cutsem, E., Pignon, J.-P., Tabernero, J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx175 · Cited by 838
Petrelli, F., Tomasello, G., Borgonovo, K., Ghidini, M., Turati, L., Dallera, P., Passalacqua, R., Sgroi, G., & Barni, S. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.4227 · Cited by 729
Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab
Yonesaka, K., Zejnullahu, K., Okamoto, I., Satoh, T., Cappuzzo, F., Souglakos, J., Ercan, D., Rogers, A., Roncalli, M., Takeda, M., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002442 · Cited by 663
CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
Pan, K., Farrukh, H., Chittepu, V. C. S. R., Xu, H., Pan, C.-X., & Zhu, Z. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02327-z · Cited by 657
Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features
Missiaglia, E., Jacobs, B., D'Ario, G., Di Narzo, A. F., Soneson, C., Budinska, E., Popovici, V., Vecchione, L., Gerster, S., Yan, P., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu275 · Cited by 646
HER2 testing in gastric cancer: a practical approach
Rüschoff, J., Hanna, W., Bilous, M., Hofmann, M., Osamura, R. Y., Penault-Llorca, F., van de Vijver, M., & Viale, G. (2012) · Modern Pathology · doi:10.1038/modpathol.2011.198 · Cited by 595
Meric-Bernstam, F., Hurwitz, H., Raghav, K. P. S., McWilliams, R. R., Fakih, M., VanderWalde, A., Swanton, C., Kurzrock, R., Burris, H., Sweeney, C., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30904-5 · Cited by 573
Holch, J. W., Ricard, I., Stintzing, S., Modest, D. P., & Heinemann, V. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2016.10.007 · Cited by 534
Siena, S., Di Bartolomeo, M., Raghav, K., Masuishi, T., Loupakis, F., Kawakami, H., Yamaguchi, K., Nishina, T., Fakih, M., Elez, E., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00086-3 · Cited by 422
Stemmler, H.-J., Schmitt, M., Willems, A., Bernhard, H., Harbeck, N., & Heinemann, V. (2007) · Anti-Cancer Drugs · doi:10.1097/01.cad.0000236313.50833.ee · Cited by 412
Ahmed, N., Salsman, V. S., Kew, Y., Shaffer, D., Powell, S., Zhang, Y. J., Grossman, R. G., Heslop, H. E., & Gottschalk, S. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1322 · Cited by 384
Venook, A. P., Niedzwiecki, D., Innocenti, F., Fruth, B., Greene, C., O'Neil, B. H., Shaw, J. E., Atkins, J. N., Horvath, L. E., Polite, B. N., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.3504 · Cited by 336
Brulé, S. Y., Jonker, D. J., Karapetis, C. S., O’Callaghan, C. J., Moore, M. J., Wong, R., Tebbutt, N. C., Underhill, C., Yip, D., Zalcberg, J. R., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.03.015 · Cited by 332
Assessment of a HER2 scoring system for colorectal cancer: results from a validation study
Valtorta, E., Martino, C., Sartore-Bianchi, A., Penaullt-Llorca, F., Viale, G., Risio, M., Rugge, M., Grigioni, W., Bencardino, K., Lonardi, S., et al. (2015) · Modern Pathology · doi:10.1038/modpathol.2015.98 · Cited by 313
Self-citationHER2 Activating Mutations Are Targets for Colorectal Cancer Treatment
Kavuri, S. M., Jain, N., Galimi, F., Cottino, F., Leto, S. M., Migliardi, G., Searleman, A. C., Shen, W., Monsey, J., Trusolino, L., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1211 · Cited by 302
Understanding the role of primary tumour localisation in colorectal cancer treatment and outcomes
Stintzing, S., Tejpar, S., Gibbs, P., Thiebach, L., & Lenz, H.-J. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.07.016 · Cited by 277
Begnami, M. D., Fukuda, E., Fregnani, J. H. T. G., Nonogaki, S., MONTAGNINI, A. L., da Costa, W. L., & Soares, F. A. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.6313 · Cited by 271
Polli, J. W., Humphreys, J. E., Harmon, K. A., Castellino, S., O’Mara, M. J., Olson, K. L., John-Williams, L. S., Koch, K. M., & Serabjit-Singh, C. J. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.018374 · Cited by 243
Richman, S. D., Southward, K., Chambers, P., Cross, D., Barrett, J., Hemmings, G., Taylor, M., Wood, H., Hutchins, G., Foster, J. M., et al. (2016) · The Journal of Pathology · doi:10.1002/path.4679 · Cited by 241
Vernieri, C., Milano, M., Brambilla, M., Mennitto, A., Maggi, C., Cona, M. S., Prisciandaro, M., Fabbroni, C., Celio, L., Mariani, G., et al. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.05.001 · Cited by 240
Antimicrobial Peptides (AMPs): Roles, Functions and Mechanism of Action
Seyfi, R., Kahaki, F. A., Ebrahimi, T., Montazersaheb, S., Eyvazi, S., Babaeipour, V., & Tarhriz, V. (2020) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-019-09946-9 · Cited by 232
Nakamura, Y., Okamoto, W., Kato, T., Esaki, T., Kato, K., Komatsu, Y., Yuki, S., Masuishi, T., Nishina, T., Ebi, H., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01553-w · Cited by 231
Li, X., Yang, C., Wan, H., Zhang, G., Feng, J., Zhang, L., Chen, X., Zhong, D., Lou, L., Tao, W., et al. (2017) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2017.01.021 · Cited by 227
Kulukian, A., Lee, P., Taylor, J., Rosler, R., de Vries, P., Watson, D., Forero-Torres, A., & Peterson, S. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0873 · Cited by 222
Ahmed, N., Salsman, V. S., Yvon, E., Louis, C. U., Perlaky, L., Wels, W. S., Dishop, M. K., Kleinerman, E. E., Pule, M., Rooney, C. M., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.133 · Cited by 215
Ross, J. S., Fakih, M., Ali, S. M., Elvin, J. A., Schrock, A. B., Suh, J., Vergilio, J., Ramkissoon, S., Severson, E., Daniel, S., et al. (2018) · Cancer · doi:10.1002/cncr.31125 · Cited by 210
Sartore-Bianchi, A., Lonardi, S., Martino, C., Fenocchio, E., Tosi, F., Ghezzi, S., Leone, F., Bergamo, F., Zagonel, V., Ciardiello, F., et al. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-000911 · Cited by 185
Self-citationGupta, E., Mick, R., Ramirez, J., Wang, X., Lestingi, T. M., Vokes, E. E., & Ratain, M. J. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.4.1502 · Cited by 182
Seo, A. N., Kwak, Y., Kim, D.-W., Kang, S.-B., Choe, G., Kim, W. H., & Lee, H. S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0098528 · Cited by 175
The role of overexpressed HER2 in transformation
Neve, R. M., Lane, H. A., & Hynes, N. E. (2001) · Annals of Oncology · doi:10.1093/annonc/12.suppl_1.s9 · Cited by 173
HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer
Sartore-Bianchi, A., Amatu, A., Porcu, L., Ghezzi, S., Lonardi, S., Leone, F., Bergamo, F., Fenocchio, E., Martinelli, E., Borelli, B., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0785 · Cited by 171
Self-citationHER2/neu testing in primary colorectal carcinoma
Ingold Heppner, B., Behrens, H.-M., Balschun, K., Haag, J., Krüger, S., Becker, T., & Röcken, C. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.483 · Cited by 169
Molecular and cellular mechanisms underlying brain metastasis of breast cancer
Hosonaga, M., Saya, H., & Arima, Y. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09881-y · Cited by 161
Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer
Siravegna, G., Lazzari, L., Crisafulli, G., Sartore-Bianchi, A., Mussolin, B., Cassingena, A., Martino, C., Lanman, R. B., Nagy, R. J., Fairclough, S., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.06.004 · Cited by 159
Self-citationRamanathan, R. K., Hwang, J. J., Zamboni, W. C., Sinicrope, F. A., Safran, H., Wong, M. K., Earle, M., Brufsky, A., Evans, T., Troetschel, M., et al. (2004) · Cancer Investigation · doi:10.1081/cnv-200039645 · Cited by 136
Raghav, K., Loree, J. M., Morris, J. S., Overman, M. J., Yu, R., Meric-Bernstam, F., Menter, D., Korphaisarn, K., Kee, B., Muranyi, A., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00226 · Cited by 132
Construction and evaluation of a novel humanized HER2-specific chimeric receptor
Sun, M., Shi, H., Liu, C., Liu, J., Liu, X., & Sun, Y. (2014) · Breast Cancer Research · doi:10.1186/bcr3674 · Cited by 125
Sforza, V., Martinelli, E., Ciardiello, F., Gambardella, V., Napolitano, S., Martini, G., della Corte, C., Cardone, C., Ferrara, M. L., Reginelli, A., et al. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i28.6345 · Cited by 123
HER-2/neu overexpression is an independent prognostic factor in colorectal cancer
Park, D. I., Kang, M.-S., Oh, S. J., Kim, H. J., Cho, Y. K., Sohn, C. I., Jeon, W. K., Kim, B. I., Han, W. K., Kim, H., et al. (2006) · International Journal of Colorectal Disease · doi:10.1007/s00384-006-0192-8 · Cited by 119
Building a Personalized Medicine Infrastructure at a Major Cancer Center
Meric-Bernstam, F., Farhangfar, C., Mendelsohn, J., & Mills, G. B. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.3043 · Cited by 112
Moretto, R., Cremolini, C., Rossini, D., Pietrantonio, F., Battaglin, F., Mennitto, A., Bergamo, F., Loupakis, F., Marmorino, F., Berenato, R., et al. (2016) · The Oncologist · doi:10.1634/theoncologist.2016-0084 · Cited by 101
Self-citationTosi, F., Sartore-Bianchi, A., Lonardi, S., Amatu, A., Leone, F., Ghezzi, S., Martino, C., Bencardino, K., Bonazzina, E., Bergamo, F., et al. (2020) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2020.06.009 · Cited by 101
Self-citationPeethambaram, P. P., Melisko, M., Rinn, K. J., Alberts, S. R., Provost, N. M., Jones, L. A., Sims, R. B., Lin, L. R. C., Frohlich, M. W., & Park, J. W. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-3282 · Cited by 86
Budi, H. S., Ahmad, F. N., Achmad, H., Ansari, M. J., Mikhailova, M. V., Suksatan, W., Chupradit, S., Shomali, N., & Marofi, F. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-02719-0 · Cited by 76
Smart CARs engineered for cancer immunotherapy
Priceman, S. J., Forman, S. J., & Brown, C. E. (2015) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000232 · Cited by 74
Schrock, A. B., Pavlick, D., Klempner, S. J., Chung, J. H., Forcier, B., Welsh, A., Young, L., Leyland-Jones, B., Bordoni, R., Carvajal, R. D., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3103 · Cited by 71
Takegawa, N., Yonesaka, K., Sakai, K., Ueda, H., Watanabe, S., Nonagase, Y., Okuno, T., Takeda, M., Maenishi, O., Tsurutani, J., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.6498 · Cited by 70
Molecular Landscape of ERBB2/ERBB3 Mutated Colorectal Cancer
Loree, J. M., Bailey, A. M., Johnson, A. M., Yu, Y., Wu, W., Bristow, C. A., Davis, J. S., Shaw, K. R., Broaddus, R., Banks, K. C., et al. (2018) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djy067 · Cited by 68
Pan, Z., Di, S., Shi, B., Jiang, H., Shi, Z., Liu, Y., Wang, Y., Luo, H., Yu, M., Wu, X., et al. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2221-1 · Cited by 64
Cenaj, O., Ligon, A. H., Hornick, J. L., & Sholl, L. M. (2019) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqz031 · Cited by 64
Fujii, S., Magliocco, A. M., Kim, J., Okamoto, W., Kim, J. E., Sawada, K., Nakamura, Y., Kopetz, S., Park, W.-Y., Tsuchihara, K., et al. (2020) · JCO Precision Oncology · doi:10.1200/po.19.00154 · Cited by 58
Immune Checkpoint Inhibitors in pMMR Metastatic Colorectal Cancer: A Tough Challenge
Marmorino, F., Boccaccino, A., Germani, M. M., Falcone, A., & Cremolini, C. (2020) · Cancers · doi:10.3390/cancers12082317 · Cited by 56
Li, P., Yang, L., Li, T., Bin, S., Sun, B., Huang, Y., Yang, K., Shan, D., Gu, H., & Li, H. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01143 · Cited by 49
Shek, D., Akhuba, L. G., Carlino, M. S., Nagrial, A. M., Moujaber, T., Read, S. A., Gao, B., & Ahlenstiel, G. (2021) · Cancers · doi:10.3390/cancers13174345 · Cited by 42
Vaccinations for Colorectal Cancer: Progress, Strategies, and Novel Adjuvants
Jiang, S., Good, D. M., & Wei, M. Q. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20143403 · Cited by 28
Luo, F., Qian, J., Yang, J., Deng, Y., Zheng, X., Liu, J., & Chu, Y. (2016) · Cell Research · doi:10.1038/cr.2016.81 · Cited by 27
Bartsch, R., Berghoff, A. S., Furtner, J., Bergen, E. S., Roider‐Schur, S., Marhold, M., Starzer, A. M., Forstner, H., Rottenmanner, B., Dieckmann, K. U., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.08.563 · Cited by 23
Tan, R. Y. C., Camat, M. D., Ng, M., Lim, T. H., Lim, A. S. T., Lim, K. H., & Tan, I. B. H. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy156 · Cited by 18
Relationship of HER2 Alteration and Microsatellite Instability Status in Colorectal Adenocarcinoma
Qiu, M., He, C., Yang, X., Yang, L., Lin, J., Zhou, D., Long, Y., Guan, W., Jin, Y., Li, Y., et al. (2021) · The Oncologist · doi:10.1002/onco.13786 · Cited by 18
Lynch, K., Squeo, G. C., Kane, W. J., Meneveau, M. O., Petroni, G. R., Olson, W. C., Chianese‐Bullock, K. A., Slingluff, C. L., Foley, E. F., & Friel, C. M. (2021) · International Journal of Cancer · doi:10.1002/ijc.33793 · Cited by 14
Lee, A. J., Jiang, J., Kumar, V., Alley, S. C., Peterson, S., & Li, J. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.08.397 · Cited by 11
Yoshino, T., Yamanaka, T., Shiozawa, M., Manaka, D., Kotaka, M., Gamoh, M., Shiomi, A., Makiyama, A., Munemoto, Y., Rikiyama, T., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz246.003 · Cited by 2
Research works printed but not linked: 10
- Laurent-Puig P, 2016, Ann Oncol, 27, Vi151
- Edenfield WJ, 2014, J Clin Oncol, 32
- Strickler JH, 2021, J Clin Oncol, 39
- Cavanna L, 2018, Oncol Lett, 15, 5787
- Clark JW, 2003, Onkologie, 26, 13
- Messersmith WA, 2019, J Natl Compr Cancer Netw, 17, 599
- Yoshino T, 2021, J Clin Oncol, 39
- Raghav KPS, 2021, J Clin Oncol, 39
- Li W, 2022, J Clin Oncol, 40
- Siena S, 2016, J Clin Oncol, 34
Cited by
Metastatic colorectal cancer: mechanisms and emerging therapeutics
Shin, A. E., Giancotti, F. G., & Rustgi, A. K. (2023) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2023.01.003 · Cited by 669
Liquid biopsy epigenomic profiling for cancer subtyping
Baca, S. C., Seo, J.-H., Davidsohn, M. P., Fortunato, B. J., Semaan, K., Sotudian, S., Lakshminarayanan, G., Dióssy, M., Qiu, X., Zarif, T. E., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02605-z · Cited by 145
Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer
Underwood, P. W., Ruff, S. M., & Pawlik, T. M. (2024) · Cells · doi:10.3390/cells13030245 · Cited by 130
“In fact, Cells 2024 , 13 , 245 9 of 16 the tucanitinib/trastuzumab combination was the topic of the MOUNTAINEER trial [70].”
BackgroundRubin, E., Shan, K. S., Dalal, S., Vu, D. U. D., Guaqueta, D. C., Naraine, A. M., & Ergle, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25021064 · Cited by 85
Targeting HER2 heterogeneity in breast and gastrointestinal cancers
Valenza, C., Guidi, L., Battaiotto, E., Trapani, D., Bianchi, A. S., Siena, S., & Curigliano, G. (2023) · Trends in cancer · doi:10.1016/j.trecan.2023.11.001 · Cited by 78
Metadata
- Authors
- Ahcene Djaballah, S., Daniel, F., Milani, A., Ricagno, G., & Lonardi, S.
- Affiliations
- Medical Oncology Unit 3, Veneto Institute of Oncology IRCCS, Padua, Italy
- Istituto Oncologico Veneto (IT)
- University of Padua (IT)
- Venue
- American Society of Clinical Oncology Educational Book
- Published
- 2022-07
- Volume
- 42
- Issue
- 42
- Pages
- 219-232
- ISSN
- 1548-8748 (ISSN-L)
- 1548-8756
- OpenAlex
- W4280492853
- Cited by
- 95
- References
- 75
- Citations by year
- 2026: 9 · 2025: 28 · 2024: 34 · 2023: 17 · 2022: 7
- FWCI
- 8.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Society of Clinical Oncology Educational Book (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- HER2, metastatic colorectal cancer, HER2 mutation, HER2 amplification, predictive biomarkers, prognostic factors, anti-EGFR therapy resistance, targeted therapy, therapeutic target
- MeSH terms
- Humans, Prognosis, Colorectal Neoplasms, Erb-b2 Receptor Tyrosine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.